

## REFERENCES

- Blacher J, Guerin AP, Pannier B, Marchais SJ, London GM. Arterial calcifications, arterial stiffness, and cardiovascular risk in end-stage renal disease. *Hypertension*. 2001;38:938-942.
- Block GA, Martin KJ, de Francisco AL, et al. Cinacalcet for secondary hyperparathyroidism in patients receiving hemodialysis. *N Engl J Med*. 2004;350:1516-1525.
- Block GA, Raggi P, Bellasi A, Kooienga L, Spiegel DM. Mortality effect of coronary calcification and phosphate binder choice in incident hemodialysis patients. *Kidney Int*. 2007;71:438-441.
- Block GA, Spiegel DM, Ehrlich J, et al. Effects of sevelamer and calcium on coronary artery calcification in patients new to hemodialysis. *Kidney Int*. 2005;68:1815-1824.
- Brown AJ, Dusso A, Slatopolsky E. Vitamin D. *Am J Physiol*. 1999;277:F157-F175.
- Campean V, Neureiter D, Varga I, et al. Atherosclerosis and vascular calcification in chronic renal failure. *Kidney Blood Press Res*. 2005;28:280-289.
- Cannata-Andía JB, Rodríguez-García M. Hyperphosphataemia as a cardiovascular risk factor – how to manage the problem. *Nephrol Dial Transplant*. 2002;17(suppl 11):16-19.
- Chen RA, Goodman WG. Role of the calcium-sensing receptor in parathyroid gland physiology. *Am J Physiol Renal Physiol*. 2004;286:F1005-F1011.
- Chertow GM, Burke SK, Raggi P; Treat to Goal Working Group. Sevelamer attenuates the progression of coronary and aortic calcification in hemodialysis patients. *Kidney Int*. 2002;62:245-252.
- Chertow GM, Raggi P, Chasan-Taber S, Bommer J, Holzer H, Burke SK. Determinants of progressive vascular calcification in haemodialysis patients. *Nephrol Dial Transplant*. 2004;19:1489-1496.
- Cardiovascular Pathology Index. Image 8, Coronary artery with calcific atherosclerosis, microscopic. Available at: <http://library.med.utah.edu/WebPath/CVHTML/CV007.html>. Accessed May 10, 2007.
- Craver L, Marco MP, Martinez I, et al. Mineral metabolism parameters throughout chronic kidney disease stages 1-5—achievement of K/DOQI target ranges. *Nephrol Dial Transplant*. 2007;22:1171-1176.

Cunningham J, Danese M, Olson K, Klassen P, Chertow GM. Effects of the calcimimetic cinacalcet HCl on cardiovascular disease, fracture, and health-related quality of life in secondary hyperparathyroidism. *Kidney Int.* 2005;68:1793-1800.

Goodman WG. Calcimimetic agents and secondary hyperparathyroidism: treatment and prevention. *Nephrol Dial Transplant.* 2002;17:204-207.

Goodman WG. Calcimimetics: a remedy for all problems of excess parathyroid hormone activity in chronic kidney disease? *Curr Opin Nephrol Hypertens.* 2005;14:355-360.

Goodman WG. Calcium and phosphorus metabolism in patients who have chronic kidney disease. *Med Clin North Am.* 2005;89:631-647.

Goodman WG. Medical management of secondary hyperparathyroidism in chronic renal failure. *Nephrol Dial Transplant.* 2003;18(suppl 3):iii2-iii8.

Goodman WG. Recent developments in the management of secondary hyperparathyroidism. *Kidney Int.* 2001;59:1187-1201.

Hoffmann U, Brady TJ, Muller J. Cardiology patient page. Use of new imaging techniques to screen for coronary artery disease. *Circulation.* 2003;108:e50-e53.

Kalantar-Zadeh K, Kuwae N, Regidor DL, et al. Survival predictability of time-varying indicators of bone disease in maintenance hemodialysis patients. *Kidney Int.* 2006;70:771-780.

Lederer E, Ouseph R. Chronic kidney disease. *Am J Kidney Dis.* 2007;49:162-171.

Levin A, Bakris GL, Molitch M, et al. Prevalence of abnormal serum vitamin D, PTH, calcium, and phosphorus in patients with chronic kidney disease: Results of the study to evaluate early kidney disease. *Kidney Int.* 2007;71:31-38.

Locatelli F, Cannata-Andía JB, Druke TB, et al. Management of disturbances of calcium and phosphate metabolism in chronic renal insufficiency, with emphasis on the control of hyperphosphataemia. *Nephrol Dial Transplant.* 2002;17:723-731.

London GM, Guerin AP, Marchais SJ, Metivier F, Pannier B, Adda H. Arterial media calcification in end-stage renal disease: impact on all-cause and cardiovascular mortality. *Nephrol Dial Transplant.* 2003;18:1731-1740.

London, GM, Marchais SJ, Alain P, Guerin AP, Metivier F. Arteriosclerosis, vascular calcifications and cardiovascular disease in uremia. *Curr Opin Nephrol Hypertens.* 2005;14:525-531.

# PTH AND MINERAL DISORDERS IN PATIENTS WITH CKD: A PRACTICAL CASE-BASED APPROACH FOR RENAL DIETITIANS

Martinez I, Saracho R, Montenegro J, Llach F. The importance of dietary calcium and phosphorous in the secondary hyperparathyroidism of patients with early renal failure. *Am J Kidney Dis.* 1997;29:496-502.

Moallem E, Kilav R, Silver J, Naveh-Many T. RNA-protein binding and post-transcriptional regulation of parathyroid hormone gene expression by calcium and phosphate. *J Biol Chem.* 1998;273:5253-5259.

Moe SM, Chertow GM, Coburn JW, et al. Achieving NKF-K/DOQI bone metabolism and disease treatment goals with cinacalcet HCl. *Kidney Int.* 2005;67:760-771.

Moe SM, Cunningham J, Bommer J, et al. Long-term treatment of secondary hyperparathyroidism with the calcimimetic cinacalcet HCl. *Nephrol Dial Transplant.* 2005;20:2186-2193.

Moe SM. Vascular calcification: hardening of the evidence. *Kidney Int.* 2006;70:1535-1537.

National Kidney Foundation. K/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease. *Am J Kidney Dis.* 2003;42(4 suppl 3):S1-S201.

National Kidney Foundation. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. *Am J Kidney Dis.* 2002;39(2 suppl 1):S1-S266.

Nemeth EF, Heaton WH, Miller M, et al. Pharmacodynamics of the type II calcimimetic compound cinacalcet HCl. *J Pharmacol Exp Ther.* 2004;308:627-635.

Phosphate metabolism. In: *The Merck Manual of Diagnosis and Therapy.* Section 2. Chapter 12.

Renagel (sevelamer hydrochloride) [package insert]. Cambridge, Mass: Genzyme Corporation; 2004.

Ritz E. The clinical management of hyperphosphatemia. *J Nephrol.* 2005;18:221-228.

Shanahan CM. Vascular calcification. *Curr Opin Nephrol Hypertens.* 2005;14:361-367.

Skorecki K, et al. *Harrison's Principles of Internal Medicine.* 15th ed. 2001:1551-1562.

Slatopolsky E, Brown A, Dusso A. Role of phosphorus in the pathogenesis of secondary hyperparathyroidism. *Am J Kidney Dis.* 2001;37(1 suppl 2):S54-S57.

Sprague SM, Llach F, Amdahl M, Taccetta C, Battle D. Paricalcitol versus calcitriol in the treatment of secondary hyperparathyroidism. *Kidney Int.* 2003;63:1483-1490.

Takeda E, Taketani Y, Morita K, et al. Molecular mechanisms of mammalian inorganic phosphate homeostasis. *Adv Enzyme Regul.* 2000;40:285-302.

Teng M, Wolf M, Ofsthun MN, et al. Activated injectable vitamin D and hemodialysis survival: a historical cohort study. *J Am Soc Nephrol.* 2005;16:1115-1125.

Tfelt-Hansen J, Brown EM. The calcium-sensing receptor in normal physiology and pathophysiology: a review. *Crit Rev Clin Lab Sci.* 2005;42:35-70.

Uribarri J, Calvo MS. Hidden sources of phosphorus in the typical American diet: does it matter in nephrology? *Semin Dial.* 2003;16:186-188.

Wang AY, Wang M, Woo J, et al. Cardiac valve calcification as an important predictor for all-cause mortality and cardiovascular mortality in long-term peritoneal dialysis patients: a prospective study. *J Am Soc Nephrol.* 2003;14:159-168.